Free Trial
NASDAQ:REVB

Revelation Biosciences Q3 2025 Earnings Report

Revelation Biosciences logo
$1.04 0.00 (0.00%)
As of 03:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revelation Biosciences EPS Results

Actual EPS
-$7.08
Consensus EPS
-$5.36
Beat/Miss
Missed by -$1.72
One Year Ago EPS
N/A

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Revelation Biosciences' next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules.

Conference Call Resources

Revelation Biosciences Earnings Headlines

REVB Poised for Big Year
Trump’s New Dollar revealed
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.tc pixel
REVB Comes to Agreement with FDA
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

View Revelation Biosciences Profile